Exicure, Inc, a clinical-stage biotechnology company developing therapeutics for hematologic diseases announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will… read more.
GERPAC Congress highlights Impedance flow cytometry is a quick and easy method for estimating the numbers and viability of bacteria in faecal microbiota samples, according to Anne-Christine Joly… read more.
Rigel Pharmaceuticals, Inc. a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that data from the ongoing Phase 1b study of R2891, a potent and… read more.
GERPAC Congress highlights Cyclodextrin-based chlorhexidine eye drops represent a promising approach to formulating stable and effective treatments for Acanthamoeba keratitis, according to researchers from the University of Picardy… read more.
Genmab A/S announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin’s lymphoma (NHL) subtypes, will… read more.
GERPAC Congress highlights The use of licensed ready-to-use (RTU) gemcitabine in polypropylene infusion bags (Sun Pharma) is associated with fewer carbon emissions than in-house compounding from glass vials,… read more.
Genentech, a member of the Roche Group announced that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio at the 67th American Society… read more.
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the 67th American Society of… read more.
GERPAC Congress highlights A near-infrared (NIR) spectroscopic method for analytical checks of compounded anti-cancer drugs could replace the current double visual checks in future, according Julie Evrard (Groupe… read more.
GERPAC Congress highlights 3D-printed doses of melatonin 1mg cost approximately half as much as the same doses prepared by manual encapsulation, according to an economic evaluation by Lena… read more.
GERPAC Congress highlights The successful development of fenfluramine-loaded albumin nanoparticles paves the way for nasal administration of fenfluramine in drug-resistant epilepsy in children. Nasal administration would deliver the… read more.
KalVista Pharmaceuticals, Inc. announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
